Acurx Pharmaceuticals Llc Stock Performance
| ACXP Stock | USD 1.35 0.05 3.85% |
The firm shows a Beta (market volatility) of 0.75, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Acurx Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Acurx Pharmaceuticals is expected to be smaller as well. At this point, Acurx Pharmaceuticals LLC has a negative expected return of -0.7%. Please make sure to confirm Acurx Pharmaceuticals' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Acurx Pharmaceuticals LLC performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Acurx Pharmaceuticals LLC has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unsteady performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in December 2024. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
1 | New to the Street Announces Its Five Corporate Interviews, Airing Episode 599 on the Fox Business Network, Tonight Monday, September 9, 2024, at 1030 PM PT Sept... | 09/09/2024 |
2 | New to the Street Announces Exclusive Bloomberg Lineup for Saturday October 12 at 630 PM EST | 10/11/2024 |
3 | New to the Street Resigns Acurx Pharmaceuticals, Inc. to Multi-Platform Media Series Featuring Broadcast Television, Earned Media, and Outdoor Advertising Suppo... | 10/14/2024 |
4 | Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference | 10/21/2024 |
5 | Acquisition by Robert DeLuccia of 250000 shares of Acurx Pharmaceuticals at 3.15 subject to Rule 16b-3 | 10/22/2024 |
6 | New to The Street to Air as Sponsored Programming on Bloomberg Friday, November 1st, Featuring Modular Medical, OriginClear With Shark Tanks Kevin Harrington, A... | 10/31/2024 |
7 | Acquisition by Donohue James J. of 50000 shares of Acurx Pharmaceuticals at 6.18 subject to Rule 16b-3 | 11/01/2024 |
8 | Acurx Pharmaceuticals Posts Earnings Results, Beats Expectations By 0.06 EPS | 11/13/2024 |
9 | Acurx Pharmaceuticals Inc Q3 2024 Earnings Call Highlights Strategic Advances Amid ... | 11/14/2024 |
10 | Bitcoin Hits New All-Time High Above 98,000 As Spot ETFs Crack 100 Billion Net Asset Value Milestone | 11/21/2024 |
| Begin Period Cash Flow | 9.1 M |
Acurx |
Acurx Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 220.00 in Acurx Pharmaceuticals LLC on August 24, 2024 and sell it today you would lose (85.00) from holding Acurx Pharmaceuticals LLC or give up 38.64% of portfolio value over 90 days. Acurx Pharmaceuticals LLC is currently does not generate positive expected returns and assumes 3.4494% risk (volatility on return distribution) over the 90 days horizon. In different words, 30% of stocks are less volatile than Acurx, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Acurx Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Acurx Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Acurx Pharmaceuticals LLC, and traders can use it to determine the average amount a Acurx Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2028
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ACXP |
Estimated Market Risk
| 3.45 actual daily | 30 70% of assets are more volatile |
Expected Return
| -0.7 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.2 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Acurx Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Acurx Pharmaceuticals by adding Acurx Pharmaceuticals to a well-diversified portfolio.
Acurx Pharmaceuticals Fundamentals Growth
Acurx Stock prices reflect investors' perceptions of the future prospects and financial health of Acurx Pharmaceuticals, and Acurx Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Acurx Stock performance.
| Return On Equity | -3.47 | ||||
| Return On Asset | -1.32 | ||||
| Current Valuation | 16.2 M | ||||
| Shares Outstanding | 16.89 M | ||||
| Price To Book | 8.24 X | ||||
| EBITDA | (14.58 M) | ||||
| Net Income | (14.58 M) | ||||
| Cash And Equivalents | 9.09 M | ||||
| Cash Per Share | 0.80 X | ||||
| Total Debt | 3.04 M | ||||
| Debt To Equity | 0.03 % | ||||
| Current Ratio | 19.43 X | ||||
| Book Value Per Share | 0.32 X | ||||
| Cash Flow From Operations | (9.8 M) | ||||
| Earnings Per Share | (1.09) X | ||||
| Market Capitalization | 21.96 M | ||||
| Total Asset | 7.71 M | ||||
| Retained Earnings | (53.22 M) | ||||
| Working Capital | 4.67 M | ||||
About Acurx Pharmaceuticals Performance
Assessing Acurx Pharmaceuticals' fundamental ratios provides investors with valuable insights into Acurx Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Acurx Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.89) | (1.99) | |
| Return On Capital Employed | (3.12) | (3.28) | |
| Return On Assets | (1.89) | (1.99) | |
| Return On Equity | (3.12) | (3.28) |
Things to note about Acurx Pharmaceuticals LLC performance evaluation
Checking the ongoing alerts about Acurx Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Acurx Pharmaceuticals LLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Acurx Pharmaceuticals generated a negative expected return over the last 90 days | |
| Acurx Pharmaceuticals may become a speculative penny stock | |
| Acurx Pharmaceuticals has high historical volatility and very poor performance | |
| Acurx Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (14.58 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Acurx Pharmaceuticals LLC currently holds about 9.09 M in cash with (9.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.8. | |
| Roughly 15.0% of the company shares are held by company insiders | |
| Latest headline from benzinga.com: Bitcoin Hits New All-Time High Above 98,000 As Spot ETFs Crack 100 Billion Net Asset Value Milestone |
- Analyzing Acurx Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Acurx Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Acurx Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Acurx Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Acurx Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Acurx Pharmaceuticals' stock. These opinions can provide insight into Acurx Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Acurx Stock Analysis
When running Acurx Pharmaceuticals' price analysis, check to measure Acurx Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acurx Pharmaceuticals is operating at the current time. Most of Acurx Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acurx Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acurx Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acurx Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.